ORGANISATION/COMPANYUniversitat de Barcelona
RESEARCH FIELDBiological sciencesComputer science
RESEARCHER PROFILERecognised Researcher (R2)
APPLICATION DEADLINE31/01/2020 00:00 - Europe/Athens
LOCATIONSpain › Barcelona
TYPE OF CONTRACTTemporary
HOURS PER WEEK37,5
OFFER STARTING DATE15/02/2020
EU RESEARCH FRAMEWORK PROGRAMMEH2020
Breast cancer (BC) is the most common cancer in women worldwide and the most-deadly one. Despite the overall good prognosis due to improved screening and new treatment strategies some challenges remain. Combination therapies in BC have been tried in several clinical trials (CT), and some are already in use in the clinics. However, despite solid pre-clinical evidence, only some patients benefit from the tested drug combinations. Single clinical trials have been underpowered to conclusively identify molecular signatures of resistance. We propose to accelerate the discovery of combination therapies and present a pipeline starting from longitudinal data and samples obtained during multiple clinical trials for a thorough and rigorous selection of drugs with synergistic potential. We are part of an European Consortia (RESCUER) that will: (1) Integrate multiple clinical trials with time point data (clinical, imaging, omics, and NGS) from unprecedented many countries aiming to answer our clinical questions; (2) Apply for the first time organoid and primary cultures of breast tumors for drug screens ex vivo to complement mouse xenograft tumor models; and (3) Develop mathematical models and statistical learners to predict treatment response at individual patient level and test new combinatorically many, treatment modalities, which will be validated in a co-clinical trial setting in parallel with mouse models and ex vivo cultures.
As a part of the consortia, we will be in charge of identifying novel mechanism of resistance to anti-ER therapies as single treatments or in combination with CDK4 inhibitors. In this project, we will have the following objectives: (1) to identify mechanisms of resistance to neoadjuvant endocrine treatment of Estrogen Receptor positive (ER) breast tumors and (2) to validate experimentally the hypothesis-models created from mathematical in silico analyses. The applicant should be in charge of the following tasks:
- Analysis and characterization of sequencing data.
- Integrative genomics and epigenomic analysis.
- Determining the interactomes of the estrogen Receptor (ER)
FBG project number
RESistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer
Gross salary per year 25.672,68€
Application letter, Curriculum vitae and contact references
Send your application to:
Job application bioinformatics
The most qualified candidates that fulfil the qualifications required will be shortlisted and called for interview.
The most qualified candidates will be called for interview. During the interview, the candidates will be asked to give a talk and meet other scientific stuff at the department. Then, the candidates will be ranked, and the position will be offered to the first ranked candidate.
Priority will be given to people with disabilities (Law 89/2015 of June 2, reserve of quota 2% in favour of people with disabilities in companies of 50 or more people).
Web site for additional job details
REQUIRED EDUCATION LEVELBiological sciences: PhD or equivalentComputer science: PhD or equivalent
REQUIRED LANGUAGESENGLISH: ExcellentSPANISH: Good
- Training in bioinformatics to analyse sequencing and proteomics data.
Knowledge in cancer biology would be considered as an additional skill.
EURAXESS offer ID: 480201
The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.
Please contact firstname.lastname@example.org if you wish to download all jobs in XML.